xMAP INSIGHTS ®
The COVID-19 Issue VO L U M E 2
Nigerian Scientists Overcome SARS-CoV-2 Testing Challenges Using xMAP® Technology Read more on page 6 > Ado Abubakar, MPH, PhD, Senior Program Officer at the Institute of Human Virology, Nigeria, and Fehintola Ige, MSc, Research Fellow at the Nigeria Institute of Medical Research
Meet xMAP® INTELLIFLEX— Technology You Trust, Versatility You Want Read more on page 8 >
Page
4
In Spain, Malaria Researchers Pivot to COVID-19 Serology Testing with xMAP® Technology
Page
5
Scientists at Johns Hopkins Meet the Moment with a Saliva-Based Serological Assay for COVID-19
xMAP INSIGHTS ®
A Magazine for the Multiplexing Community Hello xMAP Readers! Welcome to xMAP® Insights, the magazine created especially for xMAP enthusiasts. In this issue, we continue to focus on how researchers around the globe have responded to COVID-19. With vaccines being rolled out worldwide, we are beginning to see a shift in the pandemic response. Throughout this time, we’ve been humbled by the ways the xMAP Community has pivoted their research to support global efforts to stop this virus. Here are just a few of the stories shared by your peers: • Scientists at the Barcelona Institute for Global Health used their in-depth knowledge of malaria and familiarity with xMAP® Technology to refocus their research on COVID-19. • Clinical researchers at Johns Hopkins successfully developed contactless protocols for serological testing with the use of saliva samples. • Scientists in Nigeria used xMAP® Technology to help overcome SARS-CoV-2 cross-reactivity challenges. By developing a household COVID-19 serosurvey, they’ve begun to determine the impact of COVID-19 in the local community. • Even here at Luminex, our teams launched our newest instrument, xMAP® INTELLIFLEX, by implementing new prototcols to keep everyone safe and healthy while still successfully installing the first instrument overseas. As we all embrace our new normal, I’m looking forward to connecting in person sometime in 2021. In the meantime, please contact me directly at lkessler@luminexcorp.com with any story ideas you might have. Thank you for being a member of our community. Cheers to good health. All the Best,
Lisa Kessler, MBA Scientific Marketing Licensed Technologies Group Luminex Corporation
2
CONTENTS 2
Letter from the Editor
4
In Spain, Malaria Researchers Pivot to COVID-19 Serology Testing with xMAP® Technology
6
Scientists at Johns Hopkins Meet the Moment with a Saliva-Based Serological Assay for COVID-19
8
Nigerian Scientists Overcome SARS-CoV-2 Testing Challenges Using xMAP® Technology
10
Meet xMAP® INTELLIFLEX—Technology You Trust, Versatility You Want
12 xMAP® INTELLIFLEX Takes Flight
In Spain, Malaria Researchers Pivot to COVID-19 Serology Testing with xMAP® Technology by Marcha Van Der Steen During the COVID-19 pandemic, scientists in labs around the world have risen to the many challenges in impressive ways. At the Barcelona Institute for Global Health, for instance, a team including Research Professor Carlota Dobaño, PhD; Assistant Research Professor Gemma Moncunill, PhD; Staff Scientist Ruth Aguilar, PhD; and Laboratory Technician Marta Vidal, PhD quickly shifted their scientific focus and worked around the clock to help make a difference for the COVID-19 response in Spain. Dr. Dobaño, Dr. Moncunill, Dr. Aguilar, and Dr. Vidal don’t usually study coronaviruses. In fact, they don’t usually study viruses at all—their team has extensive experience in malaria research. But during their country’s worsening COVID-19 situation in early 2020, they were able to step in quickly and effectively thanks to something else they’re experts in: xMAP® Technology. At the time, they had been working successfully with the bead-based multiplexing technology for more than a decade. Information from serology samples can provide a clearer view of infection prevalence across a region. Because of this, there has been a tremendous demand for rapid, accurate, and high-throughput serological tests to identify people who have already developed antibodies to the SARS-CoV-2 virus.
Then, this team went on to use this assay to study COVID-19 exposure among healthcare workers in a study of nearly 580 people recruited between late March and early April 2020. They published the study in Nature, demonstrating that of the ~11% of participants that had antibodies to the virus, 40% had never been diagnosed. Based on these findings, the team recommended regular, ongoing RT-PCR testing for healthcare workers to ensure reliable identification of infected individuals. The ease of use and reliability of xMAP Technology made it possible for these scientists to apply the knowledge they gained from malaria testing to quickly develop an assay that could provide additional information on the source of infection in COVID-19 studies.
“We have a lot of experience with the Luminex technique and we are very happy with its performance.” The Barcelona Institute for Global Health team knew that the multiplexing capabilities of xMAP Technology would be useful for detecting several antibody isotypes against a panel of SARSCoV-2 antigens in a single reaction for faster, more sensitive, and comprehensive results. They also knew that throughput would be a make-or-break issue, so they upgraded from a Luminex® 200™ System to FLEXMAP 3D®—an xMAP platform capable of running 96- and 384-well plates—with the support of funding through the Daniel Bravo Andreu Private Foundation. “That allowed us to run more samples at the same time, and we optimized the assay to even run faster,” Dr. Aguilar said. Some of our scientists worked with the research team to transfer the assay from 96- to 384-well plates, a process that required adjustments to reagent volumes and concentrations to obtain comparable results.
The SARS-CoV-2 serology assay they developed can measure IgA, IgG, and IgM isotypes against different constructs of the spike and nucleocapsid proteins—the two more immunogenic elements of the virus. In a paper evaluating the assay's performance published in the Journal of Clinical Microbiology, Dr. Dobaño et al. describe deploying the assay for use on 128 negative control samples collected prior to the pandemic plus 104 samples from patients diagnosed with COVID-19. They found evidence for cross-reactivity of antibodies to the N protein from common cold coronaviruses against the N protein from SARS-CoV-2. Despite this, the best-performing assay signatures were 100% specific and more than 95% sensitive for identifying antibodies against SARS-CoV-2.
“We have a lot of experience with the Luminex technique and we are very happy with its performance,” Dr. Aguilar said, adding that the multiplex approach was critical in allowing her team to identify different patterns among the antibody isotypes and antigens. “The IgA response was quite interesting and seems to be very important for the detection of exposed people who do not show an IgG response. We were glad to be able to test three isotypes to multiple antigens at once, with the speed of the FLEXMAP 3D 384-well plate format.” xMAP Technology played a pivotal role in this team’s quick response to the COVID-19 pandemic, and through a collaborative effort with Luminex scientists to scale their serology assay, they provided crucial testing recommendations to their community. If you’re interested in developing your own assays, download the xMAP Cookbook to get started, or submit a Custom Services Request to our assay development team at the LuminexPLORE Lab.
xMAP® INSIGHTS | June 2021 4
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
LuminexPLORE Lab
xMAP® Custom Assay Development Services
LuminexPLORE Lab is a custom service program that uses industry-leading xMAP® Technology to offer researchers a competitive edge for scientific breakthroughs. Join our community of xMAP developers to accelerate your research. Available Services: • • • • • •
• Assay conversion • Add-on assay validation options: - Precision (intra and inter) - Sensitivity (LoD) - Cross-reactivity - Lot-lot variability - Scale-up • Advanced applications for current users
Antibody pair screening Custom coupling Custom conjugation Sample testing Assay development Optimization of existing homebrew xMAP® assay
Custom Service Workflow
Step 1
Step 2
Step 3
Submit custom service request.
Consult with Applications Scientist.
Develop assay with Luminex experts.
Reach out today to LumineXPLORE@luminexcorp.com to consult with our Applications Scientists and see what xMAP® and xTAG® can do for you. For Research Use Only. Not for use in diagnostic procedures. ©2021 Luminex Corporation. All rights reserved. Luminex, xMAP, and xTAG are trademarks of Luminex Corporation, registered in the US and other countries.
5
luminexcorp.com
xMAP® INSIGHTS | June 2021
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Scientists at Johns Hopkins Meet the Moment with a Saliva-Based Serological Assay for COVID-19 by Heather Darby
During the COVID-19 pandemic, many biologists stepped away from their usual research areas and redirected their labs’ focus to SARS-CoV-2. Some labs, however, have been working on alternatives to traditional serology assays for some time now, including Dr. Chris Heaney’s team at Johns Hopkins University, whose work over the last several years helped prepare for this exact situation. As the virus swept across the United States, Dr. Heaney and his lab were able to put their tools and expertise to use contributing to the pandemic response from the start. Dr. Heaney runs the Environmental Health Microbiology and Immunology Laboratory at Johns Hopkins where a team of scientists develop saliva-based serological assays for pathogens ranging from norovirus to Zika virus. “We had been working for years to show that the measurements you could make in saliva to detect pathogen-specific antibody responses could be equivalent to blood testing,” Dr. Heaney said. The focus on saliva came from a strong push to improve the patient experience with a non-invasive sample alternative to blood. When the COVID-19 pandemic hit, two things became clear very quickly: first, serological testing would be important to capture the true rate of exposure, and second, the need for widespread and regular testing called for a sample type that could be collected more easily than blood. For Dr. Heaney’s team, this was the perfect opportunity to contribute. They turned to xMAP® Technology, which had been the cornerstone of their previous saliva-based assays. “Saliva is a very tricky matrix,” Dr. Heaney noted. It varies widely between people, and even within the same person at different times of day. It does not perform well in solid-phase ELISAs, or with other technologies that require binding to a substrate. With xMAP Technology, though, reactions occur in solution and free-floating beads are more likely to interact directly with saliva content. Metrics such as sensitivity and specificity are significantly better for saliva-based assays run on xMAP Technology compared to solid-phase ELISAs, Heaney said. Multiplexing was also key to devising a high-quality assay. “Based on experience, we knew that if you have some duplication or some slight overlap in the multiplex antigens, it can produce better signals
in saliva, where you’re chasing a much lower concentration of leaking signal from blood into the oral compartment,” Dr. Heaney added. “Using different immunogenic targets is important to telling the full serological story.” Early in the pandemic, his team designed a multiplex assay to test for antibodies to many different SARS-CoV-2 antigens, including nucleocapsid, the receptor-binding domain, and spike proteins. Heaney compared results from this assay to blood-based serology tests and was thrilled to see comparable sensitivity and specificity performance. “With combinations of multiple nucleocapsid, receptorbinding domain, and spike protein antigens, the assay is exquisitely sensitive and specific,” he said. “We can even distinguish between individuals who have had natural infection or the vaccine.” This highly accurate, saliva-based assay made it possible for clinical researchers at Johns Hopkins to develop contactless protocols for clinical study participants and other people in need of serological testing—a measure that helped protect both those being tested and the university staff. Patients could even mail in their samples, making collection easy for everyone. Today, Dr. Heaney’s RUO test is up and running in a CAP/CLIAaccredited pathology lab at the Johns Hopkins Hospital, where it’s being used to report results to participants in clinical studies. “It’s a big milestone,” Dr. Heaney shared. “As vaccines are now more widely available, we can describe that sero-epi part of the story and fill some knowledge gaps about an individual’s exposure to the virus or response to the vaccine.” For his part, Dr. Heaney is just glad his lab could make a difference for people in the pandemic. “This is the biggest global health challenge of our generation,” he said. As scientists and healthcare workers continue to focus on the complex global threat caused by the COVID-19 pandemic, there are many downstream challenges we’ll have to navigate in the coming years. Multiplexing is a powerful tool that scientists around the world use to support assay development innovation and expand discovery in their research. If you’d like to get started building your own immunoassays, download our free xMAP Cookbook to learn more.
xMAP® INSIGHTS | June 2021 6
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
HAVE CONFIDENCE IN YOUR COVID-19 ANTIBODY TEST.
In uncertain times, laboratories need to have confidence in their COVID-19 antibody test results—which is why Luminex developed the comprehensive xMAP® SARS-CoV-2 Multi-Antigen IgG Assay. The xMAP® SARS-CoV-2 antibody assay delivers rapid and reliable detection of SARS-CoV-2 antibodies in human serum and plasma samples. By detecting three different SARS-CoV-2 antigens, the xMAP SARS-CoV-2 antibody assay may provide earlier, more sensitive results. Key Features: • Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens: • S1 subunit of the spike protein • Receptor-binding domain (RBD) of the spike protein • Nucleocapsid protein • Flexible Throughput: Test up to 96 samples in less than 3 hours • Versatile System Options: Validated on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems • Common Sample Types: Designed for use with human serum and plasma samples
luminexcorp.com ©2021 Luminex Corporation. All rights reserved. The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay has not been FDA Cleared or Approved. This test has been authorized by the FDA under an EUA for use by authorized laboratories. This test has been authorized only for the detection of antibodies against SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. §360bb-3(b)(1), unless the authorization is terminated or revoked sooner.
Stay tuned to learn more about the xMAP® SARS-CoV-2 IgG Neutralizing Antibody Assay.
Nigerian Scientists Overcome SARSCoV-2 Testing Challenges Using xMAP® Technology by Christina Olivas
Dr. Ado Abubakar and Research Fellow Fehintola Ige in front of their lab at the Nigeria Centre for Disease and Control.
At the National Reference Laboratory of the Nigeria Centre for Disease Control, a team of scientists has created an impressive laboratory infrastructure to tackle some of the country’s most challenging health problems. Their extensive public health surveillance efforts focus on malaria, neglected tropical diseases, vaccine-preventable diseases, and HIV, so it’s no wonder, then, that this team got prepared quickly when the COVID-19 pandemic arrived in Nigeria. Together with scientists from the Institute of Human Virology Nigeria, the National Reference Laboratory quickly expanded their molecular diagnostic testing capabilities to target SARS-CoV-2, supporting the country’s COVID-19 response efforts with muchneeded diagnostic and surveillance testing to identify people actively infected with SARS-CoV-2. Beyond COVID-19 diagnostics and surveillance, scientists at the Nigeria Centre for Disease Control, in partnership with scientists at the Nigeria Institute of Medical Research, also needed to determine the prevalence of SARS-CoV-2 infection across the population. This required household COVID-19 serosurveys—or serological assays that detect the presence of antibodies to SARS-CoV-2—which provide a much broader view of who had been previously infected. Ado Abubakar, MPH, PhD, Senior Program Officer at the Institute of Human Virology, Nigeria, and Fehintola Ige, MSc, Research Fellow at the Nigeria Institute of Medical Research, teamed up to conduct serological assays for SARS-CoV-2 using specimens collected during four household serosurveys across four states in Nigeria. Unfortunately, they quickly encountered problems. The single-analyte assays selected for the serosurveys lacked the specificity and sensitivity needed to detect SARS-CoV-2 antibodies with confidence.
xMAP helped circumvent cross-reactivity issues Scientists in Africa quickly learned SARS-CoV-2 serological assays may mistake antibodies for other diseases, including malaria and other human coronaviruses, for SARS-CoV-2 antibodies. In an area of the world where malaria is endemic, this was a major complicating factor. Fortunately, Dr. Abubakar and his team of highly trained scientists were veteran users of xMAP ® Technology, and had a lot of experience running customized serological assays on their fleet of MAGPIX® Systems. They partnered with Fehintola from the Nigeria Institute of Medical Research to ensure both institutions were well-acquainted with xMAP Technology. First, they addressed the accuracy challenge by using the xMAP ® SARS‑CoV‑2 Multi-Antigen IgG Assay, which multiplexes three different antigens. “Being able to use three targets in a single test was a huge advantage,” Dr. Abubakar noted. “Other assays didn’t allow this.” This critical step delivered 100% assay specificity, getting the team well on their way to developing a robust serological assay for the pandemic.
Five of the MAGPIX® Systems Dr. Ado Abubakar and his team use to test for SARS-CoV-2, HIV, and more.
xMAP® INSIGHTS | June 2021 8
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Next, they tackled the cross-reactivity problem. Thanks to the use of three targets, the false-positives triggered by malaria antibodies were already reduced. To fully assess the issue, the team of scientists tested many samples—including samples with malaria antibodies— collected prior to the pandemic, using them to establish detection thresholds so that all malaria antibodies were correctly reported as negative for SARS-CoV-2 antibodies.
Determining the impact of COVID-19 in the community With the xMAP SARS‑CoV‑2 Multi-Antigen IgG Assay in hand, the team then took on the task of completing tests for specimens from the household surveys to better understand the prevalence of COVID-19 in the country—in doing so, they began to gain a better understanding of the real-time impact of COVID-19. “This study was launched to give us the serological profile of a subset of the Nigerian population,” Fehintola said. “It gave us a snapshot of what was happening in the community.” From that project, they tested more than 5,000 samples using their xMAP assay. The results of that serosurvey showed the utility of xMAP Technology, particularly for overcoming challenges associated with cross-reactivity.
“If you’re looking at communities with a prevalence of malaria and other diseases, Luminex works best,” Dr. Abubakar said. “We recommend it for immunological studies where cross-reactivity is a problem.” Dr. Abubakar and Fehintola Ige are already using the serosurvey for another round of household COVID-19 serosurveys. The xMAP user community has a long history of using our technology to create innovative solutions to some of the most pressing problems across the world, and with more than 54,000 peer-reviewed publications citing our technologies, there’s a lot of resources available for creating and troubleshooting your own assays, or implementing existing assays to the needs of your lab, as Dr. Abubakar and his colleagues have done here. If you’re interested in developing your own custom xMAP assay, we have a team of expert scientists available to help with everything from assay optimization and add-on validation options to full assay development, antibody pair screening, and other advanced applications. Contact the LuminexPLORE Lab today for more information!
Dr. Ado Abubakar and Research Fellow Fihintola Ige using xMAP Technology to better understand the prevalence of COVID-19 in Nigeria.
xMAP® INSIGHTS | June 2021 Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
9
Meet xMAP® INTELLIFLEX
Technology You Trust, Versatility You Want by Christine Valle
INTELLIFLEX builds on the proven performance of xMAP® Technology to empower research Our Research and Development (R&D), Manufacturing, and Launch Readiness Teams worked tirelessly to develop and launch the newest platform in our xMAP® Technology family—xMAP® INTELLIFLEX. This innovative platform has exciting new features, which support low- and high-plex capabilities, offer a broad dynamic range, and quickly deliver reliable results. Additionally, INTELLIFLEX empowers users to acquire data about two parameters per target protein or nucleic acid with its new dual reporter capability, saving time and generating more data with fewer samples. Researchers are excited about this new functionality, and early access customers have successfully completed preliminary studies on pre-commercial units.
Studio setup for virtual Field Service training.
Even with all of the shifting, bringing xMAP INTELLIFLEX Systems to market has been a rewarding experience for us at Luminex. As the latest in the family of xMAP Systems, INTELLIFLEX provides a solution that can fit the needs of every research lab. To learn more about xMAP INTELLIFLEX Systems, check out this recent presentation to hear about some of the exciting applications made possible by this new platform.
Stephen Angeloni, PhD, Senior Field Application Scientist, LTG, works with INTELLIFLEX in a Rochester University lab.
The teams responsible for getting INTELLIFLEX ready had to do a lot of shifting in the pandemic Many teams at Luminex, particularly R&D and Manufacturing, have continued to work on-site to design and build units and reagents for the INTELLIFLEX Platform. Other teams have gone remote, with our Sales and Support Teams doing training online with subject matter experts at our flagship office in Austin, due to pandemic-related travel restrictions.
David Rocha, Technical Product Manager, receives units for Field Service training.
First fully remote Field Service training in the Netherlands.
Gabby Mora, Associate Product Manager, xMAP, provided sales training with live virtual demos.
xMAP® INSIGHTS | June 2021 10
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
The same xMAP Technology you love, now designed to do more. ®
xMAP INTELLIFLEX is the first xMAP multiplexing platform that combines low- and high-plex capabilities, quick time to results, and the ability to get double the data per analyte with its new dual reporter capability. ®
It’s worth getting xCITED about. Learn more at luminexcorp.com/INTELLIFLEX.
For Research Use Only. Not for use in diagnostic procedures. ©2021 Luminex Corporation. All Rights reserved. Luminex and xMAP are trademarks of Luminex Corporation, registered in the US and other countries. xMAP INTELLIFLEX is a trademark of Luminex Corporation.
xMAP® INSIGHTS | June 2021 11
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
xMAP INTELLIFLEX Takes Flight ®
The first xMAP INTELLIFLEX System traveled from Luminex’s headquarters in Austin, Texas and was installed at the Natural and Medical Science Institute (NMI) in Reutlingen, Germany by Rob Wilkens, Technical Service Supervisor, and Wilco de Jager, Senior Field Applications Scientist. ®
Luminex Corporation, Austin
Natural and Medical Sciences Institute (NMI) Reutlingen, Germany
xMAP INTELLIFLEX units ready to ship! ®
Set up and ready to go in the NMI lab! Wilco de Jager and Rob Wilkens
Wilco de Jager and Rob Wilkens
The newest generation of xMAP Technology has arrived!
xMAP Technology by the Numbers ®
®
Technology you trust. Versatility you want. Built on the proven performance of xMAP Technology, xMAP INTELLIFLEX is a modern, flow-based platform built to enhance performance and simplify the user experience.
16,000+ instruments placed
100+ 510(k) clearances
1,300 RUO kits
80+
countries
54,000+ peer-reviewed publications
70+
partners
xMAP® INSIGHTS | June 2021 12
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
COVID-19 antibody responses are complex. Profiling them shouldn’t be.
#ScienceForward
Detect N, RBD, S1, and S2 antibodies simultaneously Profile the humoral response to COVID-19 infection or vaccination with Bio-Plex Pro SARS-CoV-2 Serology Assays. Choose from IgG, IgM, or IgA-specific panels for highly sensitive and specific detection of antibodies against SARS-CoV-2 nuleocapsid protein and spike protein subunits (receptor binding domain, spike 1, and spike 2). For research use only. Not for use in diagnostic procedures. Explore research applications at bio-rad.com/SARSCoV2Serology 13
xMAP® INSIGHTS | June 2021
Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
Curiosity
Introducing
The Largest Porcine Luminex Panel On The Market
19 CONFIGURABLE ANALYTES, NO OVERNIGHT STEPS The new R&D Systems® Porcine Luminex Discovery Panel is the largest porcine panel on the market with a choice of 19 configurable target analytes. The customizable premixed panels are ideal for early-stage discovery and multiplex analysis across a range of research areas including cardiovascular, wound
healing, cancer, obesity, and toxicology. In-house proteins, antibodies and specialized diluents help ensure robust and reproducible results as well as a consistent supply of immunoassays for your long-term research, development, and animal health plans.
Learn More | visit rndsystems.com/luminexporcine
Template-ko
bio-techne.com
Global info@bio-techne.com bio-techne.com/find-us/distributors TEL +1 612 379 2956 North America TEL 800 343 7475 Europe | Middle East | Africa TEL +44 (0)1235 529449 China info.cn@bio-techne.com TEL +86 (21) 52380373 For research use or manufacturing purposes only. Trademarks and registered trademarks are the property of their respective owners.
Luminex xMAP Insights | June 2018 | Luminex supports life science research with its Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
14
LOOK CLOSER Multiplex your COVID-19 research discoveries with MILLIPLEX® immunoassays using the Luminex® platform. • MILLIPLEX® SARS-CoV-2 Antigen Panels for detection of human immunoglobulin isotypes IgG, IgM, and IgA to SARS-CoV-2 antigens: spike protein subunits S1 and S2, receptor binding domain (RBD) and nucleocapsid protein (N). • MILLIPLEX® Multiplex 48-plex Human Cytokine/ Chemokine/Growth Factor Panel A for cytokine analysis in COVID-19. • MILLIPLEX® Human Autoimmune Autoantibody Panel and Human Cytokine Autoantibody Panel for understanding autoimmunity related to SARS-CoV-2 infection. For publications and webinars demonstrating how researchers have used these and other MILLIPLEX® kits to support their COVID-19 research, visit SigmaAldrich.com/milliplex-covid-19
For Research Use Only. Not For Use In Diagnostic Procedures.
© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. Merck and the vibrant M are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources. 35804 04/2021
The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. 15
xMAP® INSIGHTS | June 2021 Luminex supports life science research with our Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
xMAP INSIGHTS ®
Looking for even more xMAP® content? Subscribe to xMAP Insights and don't forget to check out this year's xMAP® Connect!
©2021 Luminex Corporation. All Rights Reserved. Luminex, xMAP, FLEXMAP 3D, MAGPIX, and xTAG are trademarks of Luminex Corporation, registered in the US and other countries. xMAP INTELLIFLEX and Luminex 200 are trademarks of Luminex Corporation. All other trademarks are property of their respective owners. luminexcorp.com
Luminex xMAP Insights | June 2018 | Luminex supports life science research with its Research Use Only (RUO) product portfolio. Not for use in diagnostic procedures.
